Cann Group (ASX:CAN) kills the Obsidian note early and lifts the dilution overhang

Obsidian waived the 5% early redemption premium, which tells investors how this facility really ended

Cann Group (ASX:CAN) has agreed to redeem all 350,000 convertible notes still outstanding under its Obsidian Global facility, retiring the instrument less than four months after putting it in place.

The face value being cleared is US$402,500, and after netting off amounts Obsidian owed Cann on placement shares, the actual cheque the medicinal cannabis producer has to write is US$363,704. Obsidian also agreed to waive the 5% premium that would normally apply on an early redemption. That is a small but telling concession.

The key point for investors is what the redemption removes rather than what it costs. Convertible note facilities like this one create a constant supply of stock as notes convert at a discount to market, and that supply is what tends to cap the share price of small-cap names that use them. Cancelling the facility ends that mechanic.

For a Cann Group share register that has lived through years of dilution and capital reshuffles, ending a convertible facility this early is the clearest signal yet that management believes it can fund the business another way.

Why ending the Obsidian facility early matters more than the dollar amount

The US$363,704 net payment is a rounding error in the context of Cann’s cultivation and GMP facility near Mildura. The reason the announcement matters is structural, not financial.

Convertible note facilities are essentially a promise to issue new shares at a future discounted price. As long as the facility is live, every rally in the stock is met by fresh selling from the noteholder converting and exiting. Retiring the facility removes that mechanical headwind from the order book.

Obsidian waiving the 5% premium is the part worth dwelling on. Lenders only walk away from a contracted premium when they want the deal closed cleanly, which usually means they have either deployed elsewhere or no longer see the conversion economics working in their favour.

What this says about how Cann sees its own funding runway

Management put the facility in place in March 2026 and is unwinding it in June. That is a fast reversal, and companies do not typically retire dilutive capital this quickly unless the operating cash position has improved or a cleaner funding pathway has opened up.

Our take is that the redemption is a positioning move ahead of the next stage of the Botanitech and Mallee Bloom commercial story. A clean capital structure is easier to take to institutional investors than one weighed down by a live convertible facility, particularly in medicinal cannabis where the equity story has historically been the hardest part of the pitch.

The skeptical read is that the underlying business has not actually changed today. Cann still has to demonstrate that domestic and offshore demand for its dried flower, oil, vape and edible products can translate into the kind of recurring revenue that justifies a re-rate. The note redemption clears the path. It does not walk down it.

How small-cap dilution dynamics shape the read on this

ASX small caps trade on thin order books, and convertible facilities amplify that fragility because they introduce a known seller into a market that already lacks natural buyers. We have written before about why ASX small caps can swing violently on no obvious news, and convertible overhang is one of the structural reasons price discovery breaks down.

Removing the Obsidian facility takes one of those structural forces off the table for Cann. The stock can now respond to operational news on its own merits rather than being pulled lower every time a noteholder converts and sells.

The Investors Takeaway for Cann Group

The Obsidian redemption is a tidy piece of capital management that costs almost nothing and removes a real headwind. From here, the burden shifts entirely to operations. Investors will want to see the Mildura facility produce revenue growth that does not require a fresh capital raise within the next twelve months.

We would also want to see disclosure on cash balance and burn rate in the next quarterly, because retiring even a small facility says something about how comfortable the board feels with current liquidity. Investors can read our related healthcare small-cap commentary at stocksdownunder for further context.

The next data point that matters is the FY26 result and whether the Botanitech and Mallee Bloom brands have built the kind of revenue base that makes today’s redemption look like the start of a turnaround rather than a tidy footnote.